Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy.

Zhao J, Ma MZ, Ren H, Liu Z, Edelman MJ, Pan H, Mao L.

Clin Cancer Res. 2013 Jul 1;19(13):3567-76. doi: 10.1158/1078-0432.CCR-12-3478. Epub 2013 May 21.

2.

Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer.

Ren H, Chu Z, Mao L.

Mol Cancer Ther. 2009 May;8(5):1106-12. doi: 10.1158/1535-7163.MCT-08-0779. Epub 2009 May 12.

3.

HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.

Zhang J, Chen N, Qi J, Zhou B, Qiu X.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1441-9. doi: 10.1007/s00432-014-1687-2. Epub 2014 Apr 27.

PMID:
24770635
4.

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.

Clin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15.

5.

Differential proteomic analysis reveals that EGCG inhibits HDGF and activates apoptosis to increase the sensitivity of non-small cells lung cancer to chemotherapy.

Flores-Pérez A, Marchat LA, Sánchez LL, Romero-Zamora D, Arechaga-Ocampo E, Ramírez-Torres N, Chávez JD, Carlos-Reyes Á, Astudillo-de la Vega H, Ruiz-García E, González-Pérez A, López-Camarillo C.

Proteomics Clin Appl. 2016 Feb;10(2):172-82. doi: 10.1002/prca.201500008. Epub 2015 Sep 14.

PMID:
26175166
6.

Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.

Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH.

Cancer. 2011 Jul 1;117(13):2970-85. doi: 10.1002/cncr.25869. Epub 2011 Jan 10.

7.

[Expression of HDGF and its implication in stage I non-small cell lung cancer].

Zhou SJ, Xu SF, Zhang HQ, Liu ZD.

Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):927-30. Chinese.

PMID:
18478933
8.
9.

Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.

Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K.

Oncol Rep. 2005 Jun;13(6):1075-80.

PMID:
15870924
10.

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.

Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.

Cell Death Dis. 2015 Aug 6;6:e1850. doi: 10.1038/cddis.2015.217.

11.

Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA.

Cell Cycle. 2013 Nov 1;12(21):3390-404. doi: 10.4161/cc.26417. Epub 2013 Sep 17.

12.

Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.

Wang L, Liu X, Ren Y, Zhang J, Chen J, Zhou W, Guo W, Wang X, Chen H, Li M, Yuan X, Zhang X, Yang J, Wu C.

Cell Death Dis. 2017 Apr 13;8(4):e2746. doi: 10.1038/cddis.2016.409.

13.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

14.

Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.

Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, Ho CC, Chen CC, Kuo YL, Lee PY, Liu YW, Yen CC, Hsiao M, Lu PJ, Lai JM, Wang LS, Wu CH, Chiou JF, Yang PC, Huang CY.

Am J Respir Crit Care Med. 2012 Dec 1;186(11):1180-8. doi: 10.1164/rccm.201207-1180OC. Epub 2012 Sep 28.

PMID:
23024022
15.

Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.

Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L.

J Clin Oncol. 2004 Aug 15;22(16):3230-7.

PMID:
15310766
16.

Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations.

Lopez-Ayllon BD, Moncho-Amor V, Abarrategi A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R, Sastre L.

Cancer Med. 2014 Oct;3(5):1099-111. doi: 10.1002/cam4.291. Epub 2014 Jun 25.

17.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

18.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

19.

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV.

J Clin Invest. 2011 Apr;121(4):1313-28. doi: 10.1172/JCI42405. Epub 2011 Mar 23.

20.

Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.

Yang J, Fang Z, Wu J, Yin X, Fang Y, Zhao F, Zhu S, Li Y.

Tumour Biol. 2016 Oct;37(10):13871-13883. Epub 2016 Aug 2.

PMID:
27485114

Supplemental Content

Support Center